Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.30 -0.17 (-0.51%)
Streaming Delayed Price Updated: 2:14 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q2 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.
Via GlobeNewswire
News headline image
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q1 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.